GH Research’s (GHRS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of GH Research (NASDAQ:GHRS) in a report released on Wednesday,Benzinga reports. The firm currently has a $40.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group dropped their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.

GH Research Stock Performance

Shares of GHRS stock opened at $10.95 on Wednesday. The business has a 50 day moving average of $7.87 and a two-hundred day moving average of $10.33. GH Research has a 52 week low of $5.05 and a 52 week high of $14.99.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. On average, research analysts forecast that GH Research will post -0.78 EPS for the current year.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its stake in GH Research PLC (NASDAQ:GHRS) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).